507 related articles for article (PubMed ID: 28494531)
41. Is the patient activation measure associated with adherence to colonoscopy after a positive fecal occult blood test result?
Azulay R; Valinsky L; Hershkowitz F; Magnezi R
Isr J Health Policy Res; 2018 Dec; 7(1):74. PubMed ID: 30577883
[TBL] [Abstract][Full Text] [Related]
42. Multitarget stool DNA tests increases colorectal cancer screening among previously noncompliant Medicare patients.
Prince M; Lester L; Chiniwala R; Berger B
World J Gastroenterol; 2017 Jan; 23(3):464-471. PubMed ID: 28210082
[TBL] [Abstract][Full Text] [Related]
43. Colonoscopy Versus Fecal Immunochemical Test for Reducing Colorectal Cancer Risk: A Population-Based Case-Control Study.
Kim SY; Kim HS; Kim YT; Lee JK; Park HJ; Kim HM; Kang DR
Clin Transl Gastroenterol; 2021 Apr; 12(5):e00350. PubMed ID: 33928919
[TBL] [Abstract][Full Text] [Related]
44. A Clinician's Guide to Fecal Occult Blood Testing for Colorectal Cancer.
Bechtold ML; Ashraf I; Nguyen DL
South Med J; 2016 Apr; 109(4):248-55. PubMed ID: 27043809
[TBL] [Abstract][Full Text] [Related]
45. Gene expression analysis using a highly sensitive DNA microarray for colorectal cancer screening.
Koga Y; Yamazaki N; Takizawa S; Kawauchi J; Nomura O; Yamamoto S; Saito N; Kakugawa Y; Otake Y; Matsumoto M; Matsumura Y
Anticancer Res; 2014 Jan; 34(1):169-76. PubMed ID: 24403458
[TBL] [Abstract][Full Text] [Related]
46. Colonoscopy and fecal occult blood test use in Germany: results from a large insurance-based cohort.
Stock C; Ihle P; Schubert I; Brenner H
Endoscopy; 2011 Sep; 43(9):771-81. PubMed ID: 21830189
[TBL] [Abstract][Full Text] [Related]
47. Trends in colorectal cancer screening with home-based fecal occult blood tests in adults ages 50 to 64 years, 2000-2008.
Bandi P; Cokkinides V; Smith RA; Jemal A
Cancer; 2012 Oct; 118(20):5092-9. PubMed ID: 22434529
[TBL] [Abstract][Full Text] [Related]
48. Effectiveness of Screening Using Fecal Occult Blood Testing and Colonoscopy on the Risk of Colorectal Cancer: The Japan Public Health Center-based Prospective Study.
Tanaka K; Sobue T; Zha L; Kitamura T; Sawada N; Iwasaki M; Inoue M; Yamaji T; Tsugane S
J Epidemiol; 2023 Feb; 33(2):91-100. PubMed ID: 34053963
[TBL] [Abstract][Full Text] [Related]
49. Nonmedical costs of colorectal cancer screening with the fecal occult blood test and colonoscopy.
Heitman SJ; Au F; Manns BJ; McGregor SE; Hilsden RJ
Clin Gastroenterol Hepatol; 2008 Aug; 6(8):912-917.e1. PubMed ID: 18534918
[TBL] [Abstract][Full Text] [Related]
50. Participation and yield of a population-based colorectal cancer screening programme in China.
Chen H; Li N; Ren J; Feng X; Lyu Z; Wei L; Li X; Guo L; Zheng Z; Zou S; Zhang Y; Li J; Zhang K; Chen W; Dai M; He J;
Gut; 2019 Aug; 68(8):1450-1457. PubMed ID: 30377193
[TBL] [Abstract][Full Text] [Related]
51. Colorectal Cancer Screening among Korean Americans in Chicago: Does It Matter Whether They had the Screening in Korea or the US?
Lee SY
Asian Pac J Cancer Prev; 2018 May; 19(5):1387-1395. PubMed ID: 29802705
[TBL] [Abstract][Full Text] [Related]
52. Yield of repeat colonoscopy in asymptomatic individuals with a positive fecal immunochemical test and recent colonoscopy.
Kim NH; Jung YS; Lim JW; Park JH; Park DI; Sohn CI
Gastrointest Endosc; 2019 May; 89(5):1037-1043. PubMed ID: 30684602
[TBL] [Abstract][Full Text] [Related]
53. Fecal occult blood testing.
Sanford KW; McPherson RA
Clin Lab Med; 2009 Sep; 29(3):523-41. PubMed ID: 19840685
[TBL] [Abstract][Full Text] [Related]
54. Impact of continued mailed fecal tests in the patient-centered medical home: Year 3 of the Systems of Support to Increase Colon Cancer Screening and Follow-Up randomized trial.
Green BB; Anderson ML; Chubak J; Fuller S; Meenan RT; Vernon SW
Cancer; 2016 Jan; 122(2):312-21. PubMed ID: 26488332
[TBL] [Abstract][Full Text] [Related]
55. [The populations attitudes to colorectal cancer screening in the Czech Republic].
Král N; Seifert B; Suchánek Š; Zavoral M; Májek O
Epidemiol Mikrobiol Imunol; 2015 Mar; 64(1):41-6. PubMed ID: 25872995
[TBL] [Abstract][Full Text] [Related]
56. Community-based preferences for stool cards versus colonoscopy in colorectal cancer screening.
DeBourcy AC; Lichtenberger S; Felton S; Butterfield KT; Ahnen DJ; Denberg TD
J Gen Intern Med; 2008 Feb; 23(2):169-74. PubMed ID: 18157581
[TBL] [Abstract][Full Text] [Related]
57. Screening for familial colorectal cancer with a sensitive immunochemical fecal occult blood test: a pilot study.
Gimeno-García AZ; Quintero E; Nicolás-Pérez D; Hernández-Guerra M; Parra-Blanco A; Jiménez-Sosa A
Eur J Gastroenterol Hepatol; 2009 Sep; 21(9):1062-7. PubMed ID: 19307978
[TBL] [Abstract][Full Text] [Related]
58. Rates and correlates of potentially inappropriate colorectal cancer screening in the Veterans Health Administration.
Powell AA; Saini SD; Breitenstein MK; Noorbaloochi S; Cutting A; Fisher DA; Bloomfield HE; Halek K; Partin MR
J Gen Intern Med; 2015 Jun; 30(6):732-41. PubMed ID: 25605531
[TBL] [Abstract][Full Text] [Related]
59. Risk and Characteristics of Postcolonoscopy Interval Colorectal Cancer after a Positive Fecal Test: A Nationwide Population-Based Study in Korea.
Lee CK; Choi KS; Eun CS; Park DI; Han DS; Yoon M; Suh M; Jun JK
Cancer Res Treat; 2018 Jan; 50(1):50-59. PubMed ID: 28231692
[TBL] [Abstract][Full Text] [Related]
60. Sex differences in performance of fecal occult blood testing.
Brenner H; Haug U; Hundt S
Am J Gastroenterol; 2010 Nov; 105(11):2457-64. PubMed ID: 20700114
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
